Targeting the Fas/FasL system in Rheumatoid Arthritis therapy: Promising or risky?

Cytokine

Volumn 75, Issue 2, 2015, Pages 228-233

  Calmon Hamaty, Flavia ^a   Audo, Rachel ^a   Combe, Bernard ^b   Morel, Jacques ^a,b   Hahne, Michael ^a,c  

^a UNIV MONTPELLIER   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Apoptosis; Fas ligand; Fibroblast like synoviocytes; Proliferation; Rheumatoid Arthritis

Indexed keywords

FAS LIGAND; FAS ANTIGEN; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE RELEASE; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROBLAST LIKE SYNOVIOCYTE; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYNOVIUM; TARGET CELL; AGONISTS; ARTHRITIS, RHEUMATOID; CYTOLOGY; DRUG EFFECTS; ENZYME ACTIVATION; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTIGENS, CD95; APOPTOSIS; ARTHRITIS, RHEUMATOID; ENZYME ACTIVATION; FAS LIGAND PROTEIN; FIBROBLASTS; HUMANS; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939773706     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.10.004     Document Type: Review

References (73)

1. Emery P., Buch M. Treating rheumatoid arthritis with tumour necrosis factor alpha blockade. BMJ 2002, 324(7333):312-313.
2. Arend W.P., Dayer J.M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990, 33(3):305-315.
3. Olsen N.J., Stein C.M. New drugs for rheumatoid arthritis. N Engl J Med 2004, 350(21):2167-2179.
4. Mor A., Abramson S.B., Pillinger M.H. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 2005, 115(2):118-128.
5. Hashimoto H., Tanaka M., Suda T., Tomita T., Hayashida K., Takeuchi E., et al. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1998, 41(4):657-662.
6. Drynda A., Quax P.H., Neumann M., van der Laan W.H., Pap G., Drynda S., et al. Gene transfer of tissue inhibitor of metalloproteinases-3 reverses the inhibitory effects of TNF-alpha on Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. J Immunol 2005, 174(10):6524-6531.
7. Peng S.L. Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology (Oxford) 2006, 45(1):26-30.
8. Green D.R. Cancer: a wolf in wolf's clothing. Nature 2010, 465(7297):433.
9. Bodmer J.L., Schneider P., Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002, 27(1):19-26.
10. Blott E.J., Bossi G., Clark R., Zvelebil M., Griffiths G.M. Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail. J Cell Sci 2001, 114(13):2405-2416.
11. Janssen O., Qian J., Linkermann A., Kabelitz D. CD95 ligand-death factor and costimulatory molecule?. Cell Death Differ 2003, 10(11):1215-1225.
12. Sun M., Ames K.T., Suzuki I., Fink P.J. The cytoplasmic domain of Fas ligand costimulates TCR signals. J Immunol 2006, 177(3):1481-1491.
13. Schulte M., Reiss K., Lettau M., Maretzky T., Ludwig A., Hartmann D., et al. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ 2007, 14:1040-1049.
14. Wetzel M., Li L., Harms K.M., Roitbak T., Ventura P.B., Rosenberg G.A., et al. Tissue inhibitor of metalloproteinases-3 facilitates Fas-mediated neuronal cell death following mild ischemia. Cell Death Differ 2008, 15(1):143-151.
15. Mitsiades N., Yu W.H., Poulaki V., Tsokos M., Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001, 61(2):577-581.
16. Shudo K., Kinoshita K., Imamura R., Fan H., Hasumoto K., Tanaka M., et al. The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity. Eur J Immunol 2001, 31(8):2504-2511.
17. Schneider P., Holler N., Bodmer J.L., Hahne M., Frei K., Fontana A., et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998, 187(8):1205-1213.
18. Tanaka M., Itai T., Adachi M., Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998, 4(1):31-36.
19. Aoki K., Kurooka M., Chen J.J., Petryniak J., Nabel E.G., Nabel G.J. Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat Immunol 2001, 2(4):333-337.
20. Seino K., Iwabuchi K., Kayagaki N., Miyata R., Nagaoka I., Matsuzawa A., et al. Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol 1998, 161(9):4484-4488.
21. Desbarats J., Birge R.B., Mimouni-Rongy M., Weinstein D.E., Palerme J.S., Newell M.K. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 2003, 5(2):118-125.
22. Ottonello L., Tortolina G., Amelotti M., Dallegri F. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J Immunol 1999, 162(6):3601-3606.
23. Lee K.H., Feig C., Tchikov V., Schickel R., Hallas C., Schütze S., et al. The role of receptor internalization in CD95 signaling. EMBO J 2006, 25(5):1009-1023.
24. Algeciras-Schimnich A., Shen L., Barnhart B.C., Murmann A.E., Burkhardt J.K., Peter M.E. Molecular ordering of the initial signaling events of CD95. Mol Cell Biol 2002, 22(1):207-220.
25. Lavrik I., Golks A., Krammer P.H. Death receptor signaling. J Cell Sci 2005, 118(Pt 2):265-267.
26. Willis S., Day C.L., Hinds M.G., Huang D.C. The Bcl-2-regulated apoptoticpathway. J Cell Sci 2003, 116:4053-4056.
27. Cory S., Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002, 2(9):647-656.
28. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001, 15(22):2922-2933.
29. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94(4):491-501.
30. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94(4):481-490.
31. Yan N., Shi Y. Mechanisms of apoptosis through structural biology. Annu Rev Cell Dev Biol 2005, 21:35-56.
32. Lazebnik Y.A., Takahashi A., Moir R.D., Goldman R.D., Poirier G.G., Kaufmann S.H., et al. Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution. Proc Natl Acad Sci USA 1995, 92(20):9042-9046.
33. Lazebnik Y.A., Kaufmann S.H., Desnoyers S., Poirier G.G., Earnshaw W.C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994, 371(6495):346-347.
34. Mashima T., Naito M., Tsuruo T. Caspase-mediated cleavage of cytoskeletal actin plays a positive role in the process of morphological apoptosis. Oncogene 1999, 18(15):2423-2430.
35. Jin Z., El-Deiry W.S. Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol Cell Biol 2006, 26(21):8136-8148.
36. Su H., Bidère N., Zheng L., Cubre A., Sakai K., Dale J., et al. Requirement for caspase-8 in NF-kappaB activation by antigen receptor. Science 2005, 307(5714):1465-1468.
37. Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003, 114(2):181-190.
38. Pimentel-Muiños F.X., Seed B. Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity 1999, 11(6):783-793.
39. Desbarats J., Wade T., Wade W.F., Newell M.K. Dichotomy between naïve and memory CD4(+) T cell responses to Fas engagement. Proc Natl Acad Sci USA 1999, 96(14):8104-8109.
40. Desbarats J., Newell M.K. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000, 6(8):920-923.
41. Schuchmann M., Ruckert F., Garcia-Lazaro J.F., Karg A., Burg J., Knorr N., et al. MORT1/FADD is involved in liver regeneration. World J Gastroenterol 2005, 11(46):7248-7253.
42. Badorff C., Ruetten H., Mueller S., Stahmer M., Gehring D., Jung F., et al. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J Clin Invest 2002, 109(3):373-381.
43. Matsumoto N., Imamura R., Suda T. Caspase-8- and JNK-dependent AP-1 activation is required for Fas ligand-induced IL-8 production. FEBS J 2007, 274(9):2376-2384.
44. Kleber S., Sancho-Martinez I., Wiestler B., Beisel A., Gieffers C., Hill O., et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008, 13(3):235-248.
45. Park S.M., Rajapaksha T.W., Zhang M., Sattar H.A., Fichera A., Ashton-Rickardt P.G., et al. CD95 signaling deficient mice with a wild-type hematopoietic system are prone to hepatic neoplasia. Apoptosis 2008, 13(1):41-51.
46. O'reilly L.A., Tai L., Lee L., Kruse E.A., Grabow S., Fairlie W.D., et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009, 461(7264):659-663.
47. Chen L., Park S.M., Tumanov A.V., Hau A., Sawada K., Feig C., et al. CD95 promotes tumour growth. Nature 2010, 465(7297):492-496.
48. Lee J.K., Sayers T.J., Back T.C., Wigginton J.M., Wiltrout R.H. Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer. Apoptosis 2003, 8(2):151-160.
49. Mitsiades C.S., Poulaki V., Fanourakis G., Sozopoulos E., McMillin D., Wen Z., et al. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res 2006, 12(12):3705-3712.
50. Barnhart B.C., Legembre P., Pietras E., Bubici C., Franzoso G., Peter M.E. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004, 23(15):3175-3185.
51. Algeciras-Schimnich A., Pietras E.M., Barnhart B.C., Legembre P., Vijayan S., Holbeck S.L., et al. Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci USA 2003, 100(20):11445-11450.
52. Freiberg R.A., Spencer D.M., Choate K.A., Duh H.J., Schreiber S.L., Crabtree G.R., et al. Fas signal transduction triggers either proliferation or apoptosis in human fibroblasts. J Invest Dermatol 1997, 108(2):215-219.
53. Ahn J.H., Park S.M., Cho H.S., Lee M.S., Yoon J.B., Vilcek J., et al. Non-apoptotic signaling pathways activated by soluble Fas ligand in serum-starved human fibroblasts. Mitogen-activated protein kinases and NF-kappaB-dependent gene expression. J Biol Chem 2001, 276(50):47100-47106.
54. Lavrik I.N., et al. Analysis of CD95 threshold signaling: triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. J Biol Chem 2007, 282:13664-13671.
55. Schedel J., Gay R.E., Kuenzler P., Seemayer C., Simmen B., Michel B.A., et al. FLICE-inhibitory protein expression in synovial fibroblasts and at sites of cartilage and bone erosion in rheumatoid arthritis. Arthritis Rheum 2002, 46(6):1512-1518.
56. Franz J.K., Pap T., Hummel K.M., Nawrath M., Aicher W.K., Shigeyama Y., et al. Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis. Arthritis Rheum 2000, 43(3):599-607.
57. Kobayashi T., Okamoto K., Kobata T., Hasunuma T., Kato T., Hamada H., et al. Differential regulation of Fas-mediated apoptosis of rheumatoid synoviocytes by tumor necrosis factor alpha and basic fibroblast growth factor is associated with the expression of apoptosis-related molecules. Arthritis Rheum 2000, 43(5):1106-1114.
58. Santiago B., Galindo M., Rivero M., Pablos J.L. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum 2001, 44(7):1667-1676.
59. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998, 17:1675-1687.
60. Ogawa Y., Kuwahara H., Kimura T., Tani Y., Yonehara S., Shiraishi A., et al. Therapeutic effect of anti-Fas antibody on a collagen induced arthritis model. J Rheumatol 2001, 28(5):950-955.
61. Nishimura-Morita Y., Nose M., Inoue T., Yonehara S. Amelioration of systemic autoimmune disease by the stimulation of apoptosis-promoting receptor Fas with anti-Fas mAb. Int Immunol 1997, 9(12):1793-1799.
62. Zhang H., Yang Y., Horton J.L., Samoilova E.B., Judge T.A., Turka L.A., et al. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest 1997, 100(8):1951-1957.
63. Guéry L., Batteux F., Bessis N., Breban M., Boissier M.C., Fournier C., et al. Expression of Fas ligand improves the effect of IL-4 in collagen-induced arthritis. Eur J Immunol 2000, 30(1):308-315.
64. Kim S.H., Kim S., Oligino T.J., Robbins P.D. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol Ther 2002, 6(5):584-590.
65. Hoang T.R., Hammermüller A., Mix E., Kreutzer H.J., Goerlich R., Köhler H., et al. A proinflammatory role for Fas in joints of mice with collagen-induced arthritis. Arthritis Res Ther 2004, 6(5):R404-R414.
66. Ma Y., Liu H., Tu-Rapp H., Thiesen H.J., Ibrahim S.M., Cole S.M., et al. Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signaling and promotes chronic inflammation. Nat Immunol 2004, 5(4):380-387.
67. García S., Liz M., Gómez-Reino J.J., Conde C. Akt activity protects rheumatoid synovial fibroblasts from Fas-induced apoptosis by inhibition of Bid cleavage. Arthritis Res Ther 2010, 12(1):R33.
68. Sekine C., Yagita H., Kobata T., Hasunuma T., Nishioka K., Okumura K. Fas-mediated stimulation induces IL-8 secretion by rheumatoid arthritis synoviocytes independently of CPP32-mediated apoptosis. Biochem Biophys Res Commun 1996, 228(1):14-20.
69. Palao G., Santiago B., Galindo M.A., Rullas J.N., Alcamí J., Ramirez J.C., et al. Fas activation of a proinflammatory program in rheumatoid synoviocytes and its regulation by FLIP and caspase 8 signaling. Arthritis Rheum 2006, 54(5):1473-1481.
70. Audo R., Calmon-Hamaty F., Papon L., Combe B., Morel J., Hahne M. Distinct effects of soluble and membrane bound Fas ligand on fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheumatol 2014, (July 30). 10.1002/art.38806.
71. Matsuno H., Yudoh K., Nakazawa F., Sawai T., Uzuki M., Nishioka K., et al. Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera. J Rheumatol 2002, 29(8):1609-1614.
72. Smith M.D., Walker J.G. Apoptosis a relevant therapeutic target in rheumatoid arthritis?. Rheumatology (Oxford) 2004, 43(4):405-407.
73. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364(6440):806-809.